Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein.
In this study, we investigated in dogs the immunogenicity and protective immunity against Leishmania (Leishmania) chagasi infection induced by vaccination with a formulation containing the recombinant A2 protein, an amastigote specific antigen, and saponin. Vaccinated animals produced significantly increased levels of total IgG and IgG2, but not IgG1 anti-A2 antibodies, and remained negative in conventional leishmaniasis serodiagnostic methods. Significantly increased IFN-gamma and low IL-10 levels were detected in vaccinated animals before and after challenge, as compared to control animals. Importantly, while the symptoms onset appeared as early as three months after infection in most control dogs, 14 months after challenge, 5 out of 7 vaccinated dogs remained asymptomatic. Therefore, immunization with rA2 antigen was immunogenic and induced partial protection in dogs, and allowed the serological differentiation between vaccinated and infected animals, an important requirement for a canine visceral leishmaniasis (CVL) vaccine.
Fernandes
Ana Paula
AP
Department of Clinical and Toxicological Analysis, School of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. anav@uai.com.br
Costa
Míriam Maria Silva
MM
Coelho
Eduardo Antônio Ferraz
EA
Michalick
Marilene Suzan Marques
MS
de Freitas
Eloísa
E
Melo
Maria Norma
MN
Luiz Tafuri
Wagner
W
Resende
Daniela de Melo
Dde M
Hermont
Vinícius
V
Abrantes
Christiane de Freitas
Cde F
Gazzinelli
Ricardo Tostes
RT
D000818:Animals; D000953:Antigens, Protozoan / Q000235:genetics* / Q000276:immunology*; D001854:Bone Marrow Cells / Q000276:immunology; D002469:Cell Separation; D016207:Cytokines / Q000096:biosynthesis; D016054:DNA, Protozoan / Q000032:analysis / Q000302:isolation & purification; D004283:Dog Diseases / Q000276:immunology* / Q000517:prevention & control*; D004285:Dogs; D004797:Enzyme-Linked Immunosorbent Assay; D007114:Immunization; D007074:Immunoglobulin G / Q000032:analysis / Q000096:biosynthesis; D007371:Interferon-gamma / Q000032:analysis / Q000096:biosynthesis; D016753:Interleukin-10 / Q000032:analysis / Q000096:biosynthesis; D018314:Leishmania infantum / Q000276:immunology*; D007898:Leishmaniasis, Visceral / Q000276:immunology* / Q000517:prevention & control / Q000662:veterinary*; D007958:Leukocyte Count; D009000:Monocytes / Q000276:immunology / Q000378:metabolism; D015800:Protozoan Proteins / Q000235:genetics* / Q000276:immunology*; D016052:Protozoan Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014614:Vaccines, Synthetic / Q000276:immunology / Q000627:therapeutic use
C107645:A2 protein, Leishmania donovani; D000953:Antigens, Protozoan; D016207:Cytokines; D016054:DNA, Protozoan; D007074:Immunoglobulin G; D015800:Protozoan Proteins; D016052:Protozoan Vaccines; D014614:Vaccines, Synthetic; D016753:Interleukin-10; D007371:Interferon-gamma